Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis
Authors:
- 1 November 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (16) , 2314-2320
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM studyJournal of Experimental & Clinical Cancer Research, 2011
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III StudyJournal of Clinical Oncology, 2009
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentaryEuropean Journal of Cancer, 2009
- Simultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ, 2005
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- 5-Fluorouracil, Adriamycin, Cyclophosphamide (FAC) vs. 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Metastatic Breast CancerOncology, 1989